DelveInsight has launched a new report on “Biliary Tract Cancers Market Insights, Epidemiology, and Market Forecast-2030”.

 

DelveInsight’s “Biliary Tract Cancers (BTCs) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Biliary Tract Cancers (BTCs), historical and forecasted epidemiology as well as the Biliary Tract Cancers (BTCs) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some of the key facts:

• Among the EU5 countries, Germany had the highest incident population of Cholangiocarcinoma (CCA) with 4,471 cases, followed by Italy and the United Kingdom.
• As per DelveInsight insights, the incidence rate varied based on type specific cases and the estimates showed an increasing trend in the Intrahepatic CCA cases, while Extrahepatic CCA showed a decreasing trend or in some are stable cases.
• DelveInsight’s assessment based on the recent studies suggests that overall 37% of the CCA cases belongs to US in the 7M for the study period of 2017.
• Spain had the lowest incident population. As per our estimates, Japan had 4,287 incident cases of Cholangiocarcinoma (CCA) in 2017.

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market

 

Scope of the report:

• The report covers the descriptive overview of Biliary Tract Cancers (BTCs), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Biliary Tract Cancers (BTCs) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Biliary Tract Cancers (BTCs) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Biliary Tract Cancers (BTCs) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Biliary Tract Cancers (BTCs) market

 

Key companies Covered:

• Agios Pharmaceuticals
• Incyte Corporation
• Delcath Systems
• QED Therapeutics
• Nucana
• And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market

 

Biliary Tract Cancer (BTC), also known as Cholangiocarcinoma (CCA) is a rare and heterogeneous malignant neoplasm with epithelial cell origin of biliary duct and histologic and biochemical features of cholangiocyte differentiation.

The malignant tumor may arise from any portion of the bile duct i.e., from terminal ductules (canals of Hering) to the ampulla of Vater, as well as at the peribiliary glands (intramural and extramural) and sometimes may affect gall bladder.

Inflammation, cholestasis and receptor tyrosine kinases such as IL-6 receptor, c-MET and the EGFR family members are key signaling pathways in cholangiocarcinogenesis.

It can be classified anatomically based on tumor location within the biliary tree into intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA) cholangiocarcinoma subtypes. The latter two subtypes were previously grouped as extrahepatic CCA (eCCA) but are now considered distinct entities based upon differences in their tumor biology and management.

According to the ICD 10 classification of the disease, CCA is coded as intrahepatic bile duct carcinoma (C22.1), extrahepatic bile duct carcinoma (C24.0), Ampulla of Vater (C24.1), overlapping lesion of biliary tract (C24.8) (includes malignant neoplasm of biliary tract whose point of origin cannot be classified to any one of the categories); or it involves both intrahepatic and extrahepatic bile ducts (C22.0-C24.1), and Biliary tract unspecified (C24.9).

 

Whole genome sequencing performed by the International Cancer Genome Consortium revealed distinct mutations that affect prognosis. Broadly, BTCs have clusters of mutations in known oncogenes (KRAS, p53, ERBB2/HER2/NEU) and tumor suppressor genes (SMAD-4, BCL-2, p16, and p53).

Hitherto, surgical treatments are the only potentially curative therapeutic options for all the subtypes of CCA. However, the majority of CCA patients are diagnosed at late stage disease, and nearly more than one-fourth of patients considered resectable are found to be unresectable during explorative laparotomy.

 

Drugs Covered:

• Ivosidenib
• Pemigatinib
• Melphalan Hydrochloride
• Infigratinib
• Acelarin
• And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Biliary Tract Cancers (BTCs)

3. Competitive Intelligence Analysis for Biliary Tract Cancers (BTCs)

4. Biliary Tract Cancers (BTCs): Market Overview at a Glance

4.1. Biliary Tract Cancers (BTCs) Total Market Share (%) Distribution in 2017

4.2. Biliary Tract Cancers (BTCs) Total Market Share (%) Distribution in 2030

5. Biliary Tract Cancers (BTCs): Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Biliary Tract Cancers (BTCs) Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Biliary Tract Cancers (BTCs) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Biliary Tract Cancers (BTCs) Treatment and Management

8.2. Biliary Tract Cancers (BTCs) Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Biliary Tract Cancers (BTCs) Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Biliary Tract Cancers (BTCs): Seven Major Market Analysis

13.1. Key Findings

13.2. Biliary Tract Cancers (BTCs) Market Size in 7MM

13.3. Biliary Tract Cancers (BTCs) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Biliary Tract Cancers (BTCs) Total Market Size in the United States

15.1.2. Biliary Tract Cancers (BTCs) Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Biliary Tract Cancers (BTCs) Total Market Size in Germany

15.3.2. Biliary Tract Cancers (BTCs) Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Biliary Tract Cancers (BTCs) Total Market Size in France

15.4.2. Biliary Tract Cancers (BTCs) Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Biliary Tract Cancers (BTCs) Total Market Size in Italy

15.5.2. Biliary Tract Cancers (BTCs) Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Biliary Tract Cancers (BTCs) Total Market Size in Spain

15.6.2. Biliary Tract Cancers (BTCs) Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Biliary Tract Cancers (BTCs) Total Market Size in the United Kingdom

15.7.2. Biliary Tract Cancers (BTCs) Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Biliary Tract Cancers (BTCs) Total Market Size in Japan

15.8.3. Biliary Tract Cancers (BTCs) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Biliary Tract Cancers (BTCs)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Request for detailed TOC: https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market